Population and group characteristics
| Total | Exercise-induced dyspnoea | Control | p Value | |
|---|---|---|---|---|
| Subjects, n | 146 | 99 | 47 | |
| Age (years), mean (min, max) | 14.2 (13, 15) | 14.2 (13, 15) | 14.2 (13, 15) | 0.66 |
| Girls, n (%) | 88 (60.3) | 62 (62.6) | 26 (55.3) | 0.47 |
| BMI, mean (SD) | 21.0 (2.8) | 21.1 (2.8) | 20.9 (2.9) | 0.79 |
| FEV1% predicted*, mean (SD) | 92.5 (10.2) | 92.0 (10.6) | 93.5 (9.2) | 0.40 |
| Ever asthma†, n (%) | 43 (29.5) | 41 (39.8) | 2 (4.3) | <0.001 |
| Inhaled corticoid steroids‡, n (%) | 25 (17.1) | 24 (23.3) | 1 (2.1) | <0.001 |
| SABA‡, n (%) | 29 (19.7) | 26 (25.2) | 3 (6.4) | 0.004 |
| LABA‡, n (%) | 1 (0.7) | 1 (1.0) | 0 | >0.99 |
| LTRA‡, n (%) | 5 (3.4) | 5 (5.1) | 0 | 0.18 |
| Exercise tests, positive/all tested, n (%) | ||||
| EIB test | 49/146 (33.6) | 42/99 (42.4) | 7/47 (14.9) | <0.001 |
| CLE test | 11/125 (8.8) | 9/83 (10.8) | 2/42 (4.8) | 0.33 |
*Recorded before the exercise-induced bronchoconstriction test.
†Self-reported, physician diagnosed.
‡Self-reported, any use in last 3 months.
BMI, body mass index (kg/m2); CLE, continuous laryngoscopy exercise test; EIB, exercise-induced bronchoconstriction; LABA, long-acting bronchodilator agent; LTRA, leukotriene receptor antagonist; SABA, short-acting bronchodilator agent.